Organ-on-a-chip
Also known as: organ chip, organs-on-chips, tissue chip, microphysiological system
An organ-on-a-chip is a small device, often about the size of a USB stick, containing tiny channels lined with living human cells that mimic how an organ such as a lung, liver, or gut works.
Researchers use them to test how drugs and chemicals affect human tissue. While organ chips won't replace all animal testing soon, regulators are increasingly open to them, because animal results often fail to predict how drugs behave in people.
Organ-on-a-chip, explained at three levels
At home
Think of a model railway that copies a real one at small scale. An organ-on-a-chip copies a small piece of a human organ. It is a clear plastic chip with tiny channels lined with living human cells, such as lung or liver cells. Fluid flows through like blood, and some chips stretch like breathing lungs, so researchers can watch how human tissue reacts to drugs.
At work
An organ-on-a-chip is a microfluidic device containing living human cells arranged to mimic an organ's structure and function. Drug developers use it to test safety and effectiveness on human tissue before human trials. For companies, it promises earlier detection of toxic compounds, fewer costly late-stage failures, and less animal testing, which regulators increasingly accept as supporting evidence.
At home
A typical chip has two parallel channels separated by a thin porous membrane. On one side, organ cells grow, such as lung lining cells exposed to air; on the other, blood vessel cells line a channel with flowing fluid. Tiny vacuum chambers can stretch the membrane in rhythm, mimicking breathing. That mix of flow, stretch, and neighbouring cell types makes cells behave more like they do in your body than cells grown flat in a dish.
At work
Organ chips are part of new approach methodologies (NAMs), alongside organoids, 3D-printed tissues, and computer models. Chips are usually moulded from polymers such as PDMS, with pumps controlling flow and sensors measuring barrier integrity or oxygen. Applications include liver toxicity testing, disease modelling, infection studies, and testing drugs on cells derived from specific patients through stem cells. Multi-organ systems link chips, such as gut to liver, to model absorption and metabolism.
At home
A chip captures one piece of an organ, not a whole body with hormones, immune responses, and organs signalling to each other. Some chip materials, like PDMS, also soak up certain drugs, skewing results. Yet animals have their own mismatch: different species process many drugs differently. While neither is perfect, in my opinion the honest pitch is that chips are better than animals for some questions and worse for others.
At work
Adoption depends on qualification: showing that a chip predicts known human outcomes, such as drug-induced liver injury, reproducibly across labs. Regulators accept chip data through routes such as the FDA's ISTAND pilot program, and the FDA Modernization Act 2.0 allows non-animal methods before human trials. Barriers include cost per test, low throughput compared with standard cell assays, a lack of standardized protocols, and drug absorption into chip materials. Multi-organ chips add realism but also complexity.
Real-world examples
At home
Carlos, a biology student in Montreal, toured a lab using liver-on-a-chip devices. Seeing human liver cells respond to a known toxic drug the way patients had, when animal tests had missed it, convinced him to pursue the field.
At work
Lena runs preclinical safety at a Canadian biotech company. Her team added liver chips to its testing, catching a toxicity signal in a promising compound before investing in an expensive animal study and human trials.
How it compares
| feature | Organ-on-a-chip | Animal testing | Cell culture dish |
|---|---|---|---|
| Biology | Human cells | Whole animal | Human or animal cells, flat |
| Realism | Organ-level function | Whole body, different species | Limited |
| Ethics | Reduces animal use | Animal welfare concerns | Minimal concerns |
| Regulatory acceptance | Growing | Long established | Supporting evidence |
Organ chips sit between a dish of cells and a living animal, using human biology.
For analysts
For drug developers, organ chips are a way to fail faster and cheaper. I'd target them first at known weak spots, like liver toxicity, where animal tests have a poor record of predicting human outcomes.
History & origin
Microfluidics, the science of controlling tiny amounts of fluid, developed in the 1990s and 2000s. In 2010, Donald Ingber's team at Harvard's Wyss Institute published a 'lung-on-a-chip' in Science that mimicked breathing motions and responses to bacteria. Emulate, a Wyss spinout founded in 2014, commercialized organ chips, and others developed liver, kidney, and multi-organ systems. In December 2022, the US FDA Modernization Act 2.0 removed a longstanding requirement that drugs be tested in animals before human trials. In April 2025, the FDA announced plans to phase out animal testing requirements for some drug types, encouraging organ chips and computer models. In my view, organ chips matter most for a simple reason: about nine out of ten drugs that enter human trials fail, and better human-relevant testing could change that.